Claim Ledger
75% answered
Did management answer the analysts?
12 analyst questions audited.
View Claim Ledger →
Cipla Ltd — Q4 FY26
Cipla delivered a strong Q4 FY26 with India business growing 15% YoY and North America revenue of $155M.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla delivered a strong Q4 FY26 with India business growing 15% YoY and North America revenue of $155M. The company achieved key milestones including generic Ventolin approval and crossing 12,500 Cr in India revenue. Management guided for FY27 EBITDA margins of 18.5-20% with sequential improvement, driven by US respiratory launches and India chronic portfolio expansion. The US business targets a $1B run-rate by FY27-end, supported by 4 respiratory approvals and a peptide launch. Key risk: geopolitical disruptions and war-related cost inflation could pressure near-term margins.
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Geopolitical disruption and war-related cost inflation
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Business Revenue (FY26)
12,500 Cr
+15% YoY
India business crossed 12,500 Cr in FY26, growing 15% YoY in Q4.
Albuterol Market Share
19.6%
Flat YoY
Albuterol market share stood at 19.6% as of March 2026, maintaining #1 position.
US Revenue (FY26)
$780M
+14% YoY
US business reported annual revenue of $780M, supported by differentiated portfolio.
Chronic Mix (India)
60%
+2pp YoY
Chronic mix improved to 60% as per IQVIA March 2026, driven by respiratory and cardiac.
What Changed vs Last Quarter
NEW
US business to reach $1B run-rate by FY27-end
Cipla targets a $1 billion annualized run-rate for US business by end of FY27, driven by respiratory and peptide launches.
NEW
India business to deliver double-digit growth in FY27-28
Management expects strong double-digit and market-beating growth in India for FY27 and FY28.
NEW
R&D spend to remain around 7% of sales
R&D investment will continue at approximately 7% of revenue, supporting complex generics and biosimilars pipeline.
UPDATED
FY27 EBITDA margin guidance of 18.5-20%
Management expects EBITDA margins in the range of 18.5-20% for FY27, with sequential improvement and stronger H2.
DROPPED
U.S. launches: 4 respiratory and 4 peptide assets in FY27
Pipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza.
DROPPED
Lanreotide resupply expected in H1 FY27
Partner Pharmathen paused production; resupply expected in H1 FY27, with alternate site evaluation underway.
DROPPED
FY27 guidance to be provided next quarter
Management will provide FY27 guidance after finalizing the annual operating plan.
NEW RISK
Geopolitical disruption and war-related cost inflation
Ongoing geopolitical situation has started impacting operating expenses; if prolonged, could pressure margins.
NEW RISK
Lanreotide supply disruption and remediation uncertainty
Lanreotide remains off market due to partner remediation; timeline for return is uncertain, with alternate supplier filing expected by Q4 FY27.
NEW RISK
Indore facility regulatory overhang
Indore site still under regulatory scrutiny; while most filings shifted to US/Goa, any adverse outcome could delay future filings.
NEW RISK
Execution risk in US respiratory launches
Achieving $1B run-rate depends on timely approvals and commercial execution of 4 respiratory assets; any delay could impact guidance.
RISK GONE
Lanreotide supply disruption may extend beyond H1 FY27
Pharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S. revenue.
RISK GONE
U.S. launch pipeline may face delays or competition
Respiratory and peptide launches are critical to offset Lenalidomide decline; any delay or increased competition could pressure revenue.
RISK GONE
Elevated R&D spend may persist, pressuring margins
R&D at 7% of revenue is above historical 5-6% range; management expects normalization but lumpy spending could continue.
RISK GONE
Semaglutide generic launch could impact tirzepatide uptake
Analyst questioned whether Cipla's agreement with Lilly restricts entry into semaglutide; management was evasive.
🤫 Topics management stopped discussing
Mentioned in Q2 FY25, Q3 FY25, Q4 FY25
Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.
Mentioned in Q1 FY26, Q3 FY25
Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.
Mentioned in Q2 FY26, Q3 FY25
Generic Revlimid contribution expected to become immaterial from Q3 FY26, creating a revenue gap that new launches may not fully offset in the near term.
Mentioned in Q1 FY25, Q2 FY25
Goa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
Mentioned in Q1 FY26, Q2 FY26
India branded business grew only 7% YoY, below the market, due to weak acute season and team restructuring.
Fast read
Guidance and risk preview
Management expects EBITDA margins in the range of 18.5-20% for FY27, with sequential improvement and stronger H2.
Ongoing geopolitical situation has started impacting operating expenses; if prolonged, could pressure margins.
View Risks →